Vol 55, No 4 (2021)
Invited Editorial
Published online: 2021-06-16

open access

Page views 789
Article views/downloads 649
Get Citation

Connect on Social Media

Connect on Social Media

Underdiagnosis and undertreatment of migraine in Poland

Olga P. Fermo1
Pubmed: 34132384
Neurol Neurochir Pol 2021;55(4):331-332.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Olesen J. The International Classification of Headache Disorders, 3rd edition. Cephalagia. 2013; 33(9): 629–808.
  2. Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11): 954–976.
  3. Stępień A, Prusiński A, Suwa A, Klinika Neurologii Uniwersytetu Medycznego K, Pfizer Polska. Wybrane Dane Epidemiologiczne Występowania Migreny w Polsce (Selected Epidemiological Data on Migraine Prevalence in Poland).
  4. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019; 37(4): 631–649.
  5. Tepper SJ. Acute Treatment of Migraine. Neurol Clin. 2019; 37(4): 727–742.
  6. Tfelt-Hansen P, Pascual J, Ramadan N, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012; 32(1): 6–38.
  7. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
  8. Kuca B, Silberstein SD, Wietecha L, et al. COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24): e2222–e2232.
  9. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019; 381(23): 2230–2241.
  10. Croop R, Lipton RB, Kudrow D, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019; 381(2): 142–149.
  11. Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015; 84(7): 688–695.
  12. Lipton RB. Bigal ; M E, Diamond ; M, Freitag ; F, Reed ML, Stewart WF. Migraine Prevalence, Disease Burden, and the Need for Preventive Therapy. ; 2007.
  13. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004; 62(5): 788–790.
  14. Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78(17): 1337–1345.
  15. Parikh SK, Silberstein SD. Preventive Treatment for Episodic Migraine. Neurol Clin. 2019; 37(4): 753–770.
  16. Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018; 19(1): 10.
  17. Domitrz I, Lipa A, Rożniecki JJ, et al. Migraine diagnosis and treatment in Poland: a survey among primary care practitioners. Neurol Neurochir Pol. 2021.
  18. Domitrz I, Lipa A, Rożniecki J, et al. Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies. Neurol Neurochir Pol. 2020; 54(4): 337–343.



Neurologia i Neurochirurgia Polska